Amlodipine and valsartan

(Exforge®)

Amlodipine and valsartan

Drug updated on 9/4/2024

Dosage FormTablet (oral; amlodipine/valsartan: 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg, 10 mg/320 mg)
Drug ClassDihydropyridine calcium channel blockers and angiotensin II receptor blockers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled on monotherapy.
  • Indicated for the treatment of hypertension as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Exforge (amlodipine and valsartan) is indicated for the treatment of hypertension to lower blood pressure in patients not adequately controlled on monotherapy and for the treatment of hypertension as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
  • This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
  • Systolic and Diastolic Blood Pressure Reduction: Irbesartan/amlodipine ranked highest in systolic blood pressure reduction (SUCRA: 92.2%), while amlodipine/losartan ranked highest in diastolic blood pressure reduction (SUCRA: 95.1%).
  • Blood Pressure Control and Diastolic Response Rates: Telmisartan/amlodipine ranked first in blood pressure control rates (SUCRA: 83.5%), and amlodipine/losartan ranked first in diastolic response rate (SUCRA: 84.5%).
  • Amlodipine/valsartan was evaluated but no specific ranking or detailed effectiveness outcomes were provided for this combination.
  • There is no safety information available in the reviewed studies.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Exforge (amlodipine and valsartan) Prescribing Information.2021Novartis Pharmaceuticals Corporation

Systematic Reviews / Meta-Analyses